In our current work, we characterize <i>MSLN</i> levels in CRC, specifically correlating expression with clinical outcomes in relevant CRC subtypes and explore how <i>MSLN</i> expression impacts the status of immune activation and suppression in the peritumoral microenvironment. This evidence concerns the gene MSLN and colorectal carcinoma.